Parkinson's cell therapy developer files to go public
Parkinson's cell therapy developer files to go public
Aspen Neuroscience
Private
Services: Develops iPSC-derived autologous cell replacement therapies for Parkinson disease and other neurological conditions
Company Info
Upcoming Milestones & Key Dates
Q3/Q4 2026
Earnings
Q2 2026 corporate update
Recent News
Parkinson's-focused Aspen and bispecific biotech Bambusa plan IPOs
Aspen Neuroscience and Bambusa Therapeutics both disclosed IPO ambitions in SEC filings on Friday. Aspen's filing follows promising Phase 1/2a data for its autologous Parkinson's cell therapy sasineprocel; Bambusa is developing next-generation bispecific antibodies for immunology and inflammation.